SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science moves up on getting EIR for facility in Bangalore

26 Mar 2020 Evaluate
Strides Pharma Science is currently trading at Rs. 324.80, up by 5.15 points or 1.61% from its previous closing of Rs. 319.65 on the BSE.

The scrip opened at Rs. 338.00 and has touched a high and low of Rs. 346.40 and Rs. 316.40 respectively. So far 17116 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 547.35 on 14-Feb-2020 and a 52 week low of Rs. 271.00 on 20-Mar-2020.

Last one week high and low of the scrip stood at Rs. 346.40 and Rs. 271.00 respectively. The current market cap of the company is Rs. 2905.50 crore.

The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 47.24% and 21.48% respectively.

Strides Pharma Science has received the Establishment Inspection Report (EIR) form the United States Food and Drug Administration (USFDA) for its flagship facility (KRS Gardens) in Bangalore, thereby confirming the successful closure of the inspections. The facility was inspected by the USFDA in March 2020.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1005.05 4.35 (0.43%)
20-Apr-2026 12:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1238.75
Cipla 1240.00
Zydus Lifesciences 942.95
Lupin 2336.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×